Wednesday, September 17, 2014
Loading...





FDA approves Biogen's MS drug Plegridy

Biogen receives approval of treatment for multiple sclerosis patients
Posted on Aug. 15, 2014 at 12:00 a.m. | Updated on Aug. 15, 2014 at 7:27 p.m.

CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker’s new treatment for people with relapsing forms of multiple sclerosis.

The company said Friday that the Food and Drug Administration cleared the injectable drug, dubbed Plegridy, after reviewing results from a study that involved more than 1,500 people with the disease.

Multiple sclerosis is a disease of the immune system in which the body attacks the brain and spinal cord.

Its symptoms can come and go, often reappearing months later.

The European Commission recently approved Plegridy.

Biogen also markets the multiple sclerosis drugs Avonex and Tysabri.

Shares of Biogen Idec Inc. ended regular trading up $5.46, or 1.6 percent, to $342.47 on Friday.

The stock is up 22 percent this year.




 FILE - In this Wednesday, Oct. 31, 2012 file photo, an ambulance departs Bellevue Hospital in New York where patients were being evacuated. When Superstorm Sandy slammed into the Northeast nearly two years ago, hospitals found themselves dealing with surges in patients, lost power supplies and employees who couldn’t get to work _ problems that a new federal report finds they were not prepared to handle. The U.S. Department of Health and Human Service’s Inspector General Office released a study Wednesday Sept. 17, 2014 on the emergency preparedness and response during the storm at 172 hospitals in the hardest-hit areas of New York, most of Connecticut and all of New Jersey. (AP Photo/Mark Lennihan, File)

Updated 1 hour ago

Updated 1 hour ago
Back to top ^